inclusion criteria: - individuals must meet all of the following criteria to be included in the study: - laboratory-confirmed sars-cov-2 infection as determined by either a documented positive molecular assay/ other commercial or public health assay in any specimen collected < 5 days prior to screening or a documented positive molecular assay ≥ 5 days prior to screening and confirmed by polymerase chain reaction (pcr) at screening. - illness of any duration with oxygen saturation > 93% at room air, heart rate ≤ 100 beats per minute at rest, and no evidence of respiratory distress with respiration rate < 20 breaths per minute. - able to provide informed consent. - aged ≥ 19 and ≤ 75 years. - absolute lymphocyte count <1,500 lymphocytes/µl. - avoid becoming pregnant or impregnate a partner through 90 days after study agent administration. females must agree to 2 methods of contraception, and males to at least one method of contraception. - not participate in any other clinical trial for an investigational therapy through day 30.

inclusion criteria: - individuals must meet all of the following criteria to be included in the study: - laboratory-confirmed sars-cov-2 infection as determined by either a documented positive molecular assay/ other commercial or public health assay in any specimen collected < 5 days prior to screening or a documented positive molecular assay ≥ 5 days prior to screening and confirmed by polymerase chain reaction (pcr) at screening. - illness of any duration with oxygen saturation > 93% at room air, heart rate ≤ 100 beats per minute at rest, and no evidence of respiratory distress with respiration rate < 20 breaths per minute. - able to provide informed consent. - aged ≥ 19 and ≤ 75 years. - absolute lymphocyte count <1,500 lymphocytes/µl. - avoid becoming pregnant or impregnate a partner through 90 days after study agent administration. females must agree to 2 methods of contraception, and males to at least one method of contraception. - not participate in any other clinical trial for an investigational therapy through day 30.

inclusion criteria: - individuals must meet all of the following criteria to be included in the study: - laboratory-confirmed sars-cov-2 infection as determined by either a documented positive molecular assay/ other commercial or public health assay in any specimen collected < 5 days prior to screening or a documented positive molecular assay ≥ 5 days prior to screening and confirmed by polymerase chain reaction (pcr) at screening. - illness of any duration with oxygen saturation > 93% at room air, heart rate ≤ 100 beats per minute at rest, and no evidence of respiratory distress with respiration rate < 20 breaths per minute. - able to provide informed consent. - aged ≥ 18 and ≤ 75 years. - absolute lymphocyte count <1,500 lymphocytes/µl. - avoid becoming pregnant or impregnate a partner through 90 days after study agent administration. females must agree to 2 methods of contraception, and males to at least one method of contraception. - not participate in any other clinical trial for an investigational therapy through day 30.

inclusion criteria: - individuals must meet all of the following criteria to be included in the study: - laboratory-confirmed sars-cov-2 infection as determined by either a documented positive molecular assay/ other commercial or public health assay in any specimen collected < 5 days prior to screening or a documented positive molecular assay ≥ 5 days prior to screening and confirmed by polymerase chain reaction (pcr) at screening. - illness of any duration with oxygen saturation > 93% at room air, heart rate ≤ 100 beats per minute at rest, and no evidence of respiratory distress with respiration rate < 20 breaths per minute. - able to provide informed consent. - aged ≥ 18 and ≤ 75 years. - absolute lymphocyte count <1,500 lymphocytes/µl. - avoid becoming pregnant or impregnate a partner through 90 days after study agent administration. females must agree to 2 methods of contraception, and males to at least one method of contraception. - not participate in any other clinical trial for an investigational therapy through day 30.